Marijana Vujkovic, PhD, MSCE
Assistant Professor of Medicine and Epidemiology
Intergovernmental Personnel, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Member, Penn Center for Nutritional Science and Medicine
Member, Penn Center for Molecular Studies in Digestive and Liver Diseases
Senior Fellow, Penn Institute for Biomedical Informatics
Department: Medicine
Graduate Group Affiliations
Contact information
Division of Translational Medicine and Human Genetics
Smilow Center for Translational Research
Suite 11-134
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-573-6323
Email: vujkovic@pennmedicine.upenn.edu

Dr. Vujković is trained in Computer Science, Clinical Epidemiology, and Population Genetics. Her NIH-funded research program aims to advance the understanding of genetics underlying obesity-induced diseases to enable personalized disease risk assessment and intervention. Her lab is focused on identifying and quantifying the role of actionable clinical factors in moderating the genetic risk for non-alcoholic fatty liver disease and subsequent progression to cirrhosis and liver cancer. Her team has developed a scalable genomics-informed pharmaco-epidemiologic research program to accelerate drug-discovery efforts, focusing on the repurposing of existing medications for novel indications.
Marijana obtained her BSc in Computer Science, MSc and PhD doctorate in Epidemiology at Erasmus University Rotterdam in the Netherlands. She moved to the United States for a post-doctoral fellowship in Precision Oncology at the Children’s Hospital of Philadelphia prior to becoming a faculty member at the University of Pennsylvania.
Dr. Vujković is an investigator in in the Million Veteran Program at the US Department of Veteran Affairs, where in 2019 she received the Million Veteran Program Early Career Investigator Award. Her research productivity is evidenced by 70+ peer-reviewed publications, which includes two first-author publications in ’Nature Genetics’, and a shared senior authorship in ’Nature’ as part of the T2D Global Genomics Initiative.



